Cellyan Biotechnology (HKPD) Debt Ratio (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Debt Ratio of 0.28 for Q3 2025, up 127.57% year-over-year from 0.12 in Q3 2024, and down 13.25% quarter-over-quarter from 0.32 in Q1 2025.
Cellyan Biotechnology (HKPD) Debt Ratio (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Debt Ratio for 2 consecutive years, with 0.28 the latest figure, recorded in Q3 2025.
- In Q3 2025, Debt Ratio rose 127.57% year-over-year to 0.28; the TTM figure through Sep 2025 stood at 0.28 (up 127.57% YoY), while the FY2025 annual figure was 0.32, up 112.96% from the prior year.
- Debt Ratio slipped to 0.28 in Q3 2025 per HKPD's latest filing, from 0.32 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.32 in Q1 2025 and bottomed at 0.12 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.57 Bn | 97.41 Bn | 3.69 Bn | 0.12 |
| 2 | Cencora | 61.35 Bn | 58.53 Bn | 3.61 Bn | 0.14 |
| 3 | Cardinal Health | 54.15 Bn | 49.30 Bn | 2.56 Bn | 0.16 |
| 4 | Henry Schein | 10.05 Bn | 9.89 Bn | 1.10 Bn | 0.29 |
| 5 | Akso Health | 671.90 Mn | 671.70 Mn | - | 0.00 |
| 6 | Edap Tms | 154.62 Mn | 133.07 Mn | 7.34 Mn | 0.52 |
| 7 | Accendra Health | 90.69 Mn | 83.04 Mn | 263.41 Mn | 0.82 |
| 8 | 111 | 31.31 Mn | -27.44 Mn | 18.18 Mn | 0.13 |
| 9 | Cosmos Health | 13.28 Mn | 10.84 Mn | 1.51 Mn | 0.19 |
| 10 | Cellyan Biotechnology | 6.70 Mn | 6.48 Mn | - | 0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.07 |
| Sep 30, 2025 | 0.28 |
| Mar 31, 2025 | 0.32 |
| Sep 30, 2024 | 0.12 |
| Mar 31, 2024 | 0.15 |